Strategic Asset Leasing Inc (LEAS)

[billdean8]

Merger Sub

Anew Medical Sub, Inc. is a wholly owned subsidiary of Redwoods formed solely for the purpose of effectuating the Merger described herein. Merger Sub was incorporated under the laws of Wyoming as a corporation on May 12, 2023. Merger Sub owns no material assets and does not operate any business.

The mailing address of Merger Sub’s principal executive office is 1115 Broadway, 12th Floor, New York, NY 10010. Its telephone number is [phone]. After the consummation of the business combination, Merger Sub will cease to exist as a separate legal entity.

ANEW

ANEW MEDICAL, INC. is a Wyoming corporation originally formed in Nevada on August 2, 2004 as Technigen Corp. On February 27, 2006, the company changed its name to Vision Dynamics Inc and on May 22, 2006, the company changed its name to Mommoth Energy Group, Inc. On March 5, 2013, the company as re-domiciled in Wyoming and on October 2, 2014 changed its name to Strategic Asset Leasing Inc. On January 4, 2022, Strategic Asset Leasing, Inc. (“LEAS”) officially changed its name to ANEW MEDICAL, INC. under the rules of the State of Wyoming. However, this name change has not been declared effective by FINRA. LEAS is referred to this proxy statement/prospectus supplement as “ANEW MEDICAL, INC.,” “ANEW” or “ANEW MEDICAL”. Upon closing of the Business Combination, the Combined Company’s name will be changed to ANEW MEDICAL, INC. On November 1, 2021, the company acquired ANEW Oncology, Inc., a Delaware corporation as a wholly-owned subsidiary.

ANEW MEDICAL is dedicated to realizing the potential of biologic, cell and gene therapies to offer transformative patient outcomes in areas of high unmet medical need by extending the reach of protein, cell, and gene therapies to highly prevalent neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease as they are universally fatal neurodegenerative diseases. The company has assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. The lead product candidates are the gene therapy candidate for ALS therapy termed AMI-202 (“AAV.myo-s-KL”), and the gene therapy candidate for Alzheimer’s diseases termed AMI-101 (“AAV9-s-KL”). All of these candidates are in pre-clinical development.

The company plans on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic.

The mailing address of ANEW MEDICAL’s principal executive office is 13576 Walnut Street Omaha, NE 68144. Its telephone number is [phone].

ANEW MEDICAL’s common stock is currently traded on the Pink market tier of the OTC Markets Group under the trading symbol “LEAS.” The closing price of ANEW MEDICAL’s common stock on February 9, 2024 was $0.0016.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001907223/000121390024013467/fs42024a8_redwoods.htm